Comparison of the pharmacokinetics and pharmacodynamics of YH4808 in healthy subjects for defining an appropriate dosing regimen
Open Access
- 1 September 2021
- journal article
- research article
- Published by Korean Society for Clinical Pharmacology and Therapeutics in Translational and Clinical Pharmacology
- Vol. 29 (3) , 150-159
Abstract
YH4808 is a novel potassium-competitive acid blocker developed for gastric acid-related disorders. Previous studies indicate its potential to improve symptoms of gastric acid-related disorders. The current study was aimed to find the optimal regimen of YH4808 for night time pH control. This study was performed in two parts. Each was a randomized, open-label, active-controlled, multiple-doses, two-treatment, two-period crossover study conducted in 20 healthy Korean volunteers. Subjects were randomly assigned to one of the four groups. The three groups received different dosage regimens of YH4808 (100 mg twice a day, 200 mg once a day, or 200 mg twice a day), and the fourth group received esomeprazole 40 mg twice a day. The pharmacokinetic parameters demonstrated that the systemic exposure of YH4808 increased in a dose-proportional manner. The difference in the proportion of time above pH 4 over 24 h from the baseline was the greatest in the group receiving YH4808 200 mg twice a day. The values of the area under the effect curve at night time (12 A.M.-7 A.M.) were higher in all YH4808 groups than in the esomeprazole group. However, the differences among the YH4808 groups were not statistically significant (p > 0.05). YH4808 exhibited potential for better pH control during the night in comparison to esomeprazole. The optimal regimen for night time pH control among all the YH4808 regimens was 200 mg twice a day.Keywords
Funding Information
- Yuhan corp
This publication has 10 references indexed in Scilit:
- Pharmacodynamic evaluation of YH4808 for Helicobacter pylori eradication in healthy subjectsTranslational and Clinical Pharmacology, 2020
- Role of Acid Suppression in Acid-related Diseases: Proton Pump Inhibitor and Potassium-competitive Acid BlockerJournal of Neurogastroenterology and Motility, 2019
- A novel K+ competitive acid blocker, YH4808, sustains inhibition of gastric acid secretion with a faster onset than esomeprazole: randomised clinical study in healthy volunteersAlimentary Pharmacology & Therapeutics, 2017
- Efficacy of Vonoprazan for Proton Pump Inhibitor-Resistant Reflux EsophagitisDigestion, 2017
- Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015Journal of Gastroenterology, 2016
- Evidence-based clinical practice guidelines for peptic ulcer disease 2015Journal of Gastroenterology, 2016
- Editorial: towards extended acid suppression - the search continuesAlimentary Pharmacology & Therapeutics, 2015
- Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised editionJournal of Gastroenterology and Hepatology, 2014
- Potassium-competitive acid blockade: A new therapeutic strategy in acid-related diseasesPharmacology & Therapeutics, 2005
- Pharmacological and pharmacodynamic essentials of H2-receptor antagonists and proton pump inhibitors for the practising physicianBest Practice & Research Clinical Gastroenterology, 2001